AGN 2.47% 79.0¢ argenica therapeutics limited

Ann: First Patient Dosed in Phase 2 Stroke Trial of ARG-007, page-23

  1. 1,062 Posts.
    lightbulb Created with Sketch. 196
    You are correct in they do need capital, and they themselves have stated it. The positive with these guys is that if you look back at their financials, they are extremely fiscally responsible. So a cap raise is going to happen at some stage soon, but this could be a CU6 type of situation, where the raise happens at $1+ and possibly be pro rata.

    So investors don't be disappointed by a cap raise, I feel this company knows how to spend well. Very rare. This is up there with RAC, EMV in terms of companies who value the cash and not raise perpetually like most biotechs.

 
watchlist Created with Sketch. Add AGN (ASX) to my watchlist
(20min delay)
Last
79.0¢
Change
-0.020(2.47%)
Mkt cap ! $98.34M
Open High Low Value Volume
81.0¢ 81.0¢ 79.0¢ $28.63K 35.98K

Buyers (Bids)

No. Vol. Price($)
2 8439 79.0¢
 

Sellers (Offers)

Price($) Vol. No.
80.0¢ 5446 3
View Market Depth
Last trade - 11.25am 29/07/2024 (20 minute delay) ?
AGN (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.